These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27734205)

  • 1. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.
    McNamara MJ; Adelstein DJ; Allende DS; Bodmann JW; Ives DI; Murthy SC; Raymond D; Raja S; Rodriguez CP; Sohal D; Stephans KL; Videtic GMM; Rybicki LA
    J Gastrointest Cancer; 2017 Jun; 48(2):181-189. PubMed ID: 27734205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesophageal junction.
    McNamara MJ; Adelstein DJ; Bodmann JW; Greskovich JF; Ives DI; Mason DP; Murthy SC; Rice TW; Saxton JP; Sohal D; Stephans K; Rodriguez CP; Videtic GM; Rybicki LA
    J Thorac Oncol; 2014 Oct; 9(10):1561-7. PubMed ID: 25170643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
    Thukral A; Metz J; Hwang WT; O'Dwyer P; Plastaras J; Both S; Bar-Ad V
    Dis Esophagus; 2011 Jul; 24(5):330-6. PubMed ID: 21143694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen.
    McNamara MJ; Rybicki LA; Sohal D; Allende DS; Videtic GM; Rodriguez CP; Stephans KL; Murthy SC; Raja S; Raymond D; Ives DI; Bodmann JW; Adelstein DJ
    J Gastrointest Oncol; 2016 Apr; 7(2):196-205. PubMed ID: 27034786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
    Bascoul-Mollevi C; Gourgou S; Galais MP; Raoul JL; Bouché O; Douillard JY; Adenis A; Etienne PL; Juzyna B; Bedenne L; Conroy T
    Eur J Cancer; 2017 Oct; 84():239-249. PubMed ID: 28829992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcome and Implications for Trial Design.
    Kleinberg LR; Catalano PJ; Forastiere AA; Keller SM; Mitchel EP; Anne PR; Benson AB
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):738-46. PubMed ID: 26972646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
    Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
    Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
    Gerber N; Ilson DH; Wu AJ; Janjigian YY; Kelsen DP; Zheng J; Zhang Z; Bains MS; Rizk N; Rusch VW; Goodman KA
    Dis Esophagus; 2014 Apr; 27(3):235-41. PubMed ID: 23796070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial.
    Alderson D; Cunningham D; Nankivell M; Blazeby JM; Griffin SM; Crellin A; Grabsch HI; Langer R; Pritchard S; Okines A; Krysztopik R; Coxon F; Thompson J; Falk S; Robb C; Stenning S; Langley RE
    Lancet Oncol; 2017 Sep; 18(9):1249-1260. PubMed ID: 28784312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.
    Yoon DH; Jang G; Kim JH; Kim YH; Kim JY; Kim HR; Jung HY; Lee GH; Song HY; Cho KJ; Ryu JS; Kim SB
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):489-96. PubMed ID: 25680595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
    Adelstein DJ; Rice TW; Becker M; Larto MA; Kirby TJ; Koka A; Tefft M; Zuccaro G
    Cancer; 1997 Sep; 80(6):1011-20. PubMed ID: 9305700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    Glatz T; Bronsert P; Schäfer M; Kulemann B; Marjanovic G; Sick O; Hopt UT; Zirlik K; Makowiec F; Hoeppner J
    Eur J Surg Oncol; 2015 Oct; 41(10):1300-7. PubMed ID: 26253194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
    Swisher SG; Winter KA; Komaki RU; Ajani JA; Wu TT; Hofstetter WL; Konski AA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1967-72. PubMed ID: 21507583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction.
    Strandby RB; Svendsen LB; Bæksgaard L; Egeland C; Achiam MP
    Scand J Surg; 2016 Jun; 105(2):97-103. PubMed ID: 26250355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.